March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. These ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company ...

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...

In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...